Miles Capital’s Biogen BIIB Stock Holding History

Miles Capital’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-1,565	Closed	-$518K	–	135
2014 Q3	$518K	Buy	+1,565	New	+$516K	0.27%	75

Other funds holding BIIB

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Miles Capital's BIIB Position: Q4 2014 in Review

Miles Capital sold out of Biogen (BIIB) in Q4 2014, closing a stake of 1,565 shares — an estimated $518K sold.

Miles Capital first reported a position in BIIB in Q3 2014 and held it in 1 quarter. The position peaked at $518K in Q3 2014. 885 funds tracked by Wall St. Rank hold BIIB as of Q4 2014.

Miles Capital reported no remaining Biogen position as of Q4 2014 after selling out during the quarter.
Miles Capital sold 1,565 Biogen shares in Q4 2014, an estimated $518K.
Miles Capital first reported a position in Biogen in Q3 2014 and held it in 1 quarter.
Miles Capital's Biogen position peaked at $518K in Q3 2014.
885 funds tracked by Wall St. Rank held Biogen as of Q4 2014.

Based on Miles Capital's 13F filing for Q4 2014, filed 12 Feb 2015.